Is Eli Lilly and Company (LLY) overvalued? · P/E 39, rev $65.18B
Eli Lilly and Company (LLY) is a drug manufacturers - general company listed on NYSE. It is led by David Ricks.
This page asks whether Eli Lilly and Company (LLY) looks expensive on cached numbers — not a short thesis.
Latest reported LLY revenue for 2025-12-31 was $65.18B. Net income was $20.64B. Revenue was up 44.7% from 2024-12-31 to 2025-12-31. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
LLY currently screens at market cap $991.62B and trailing P/E 39.5. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next LLY 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the LLY stock page for the full model, not this heading.
Not investment advice.